Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Bionomics Limited (BNOX) is a biotechnology company focused on developing innovative treatments for central nervous system disorders. Its lead product candidates include BNC210 for anxiety and BNC101 for cancer, targeting markets primarily in the United States and Australia. The company's competitive edge lies in its proprietary drug delivery technologies and a robust pipeline of clinical-stage assets.
Bionomics generates revenue primarily through partnerships with pharmaceutical companies for clinical trials and drug development. Its competitive advantages include a strong intellectual property portfolio and a focus on unmet medical needs, which allows for premium pricing on successful products.
Clinical trial results for BNC210 and BNC101
Partnership announcements with larger pharmaceutical companies
Regulatory approvals from the FDA or EMA
Market dynamics in the CNS disorder treatment space
Regulatory changes affecting drug approval processes
Technological disruption in drug development methodologies
Emergence of new competitors with similar CNS drug candidates
Potential for larger pharmaceutical companies to dominate the market
High cash burn rate leading to potential liquidity issues if funding is not secured
Dependency on successful clinical trial outcomes for future funding
moderate - The biotechnology sector can be sensitive to economic cycles, particularly regarding funding for R&D and consumer health spending.
High interest rates can increase the cost of financing for biotech firms, potentially affecting their ability to fund clinical trials and operations.
minimal - Bionomics has no debt, reducing its exposure to credit conditions.
growth - Investors looking for high-risk, high-reward opportunities in biotechnology.
high - The stock has exhibited extreme volatility, with a 1-year return of -98%.
